Advertisement

Topics

EMA approval for adalimumab biosimilar Imraldi

05:08 EDT 30 Jun 2017 | Generics and Biosimilars Initiative

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on 23 June 2017 that it had recommended granting marketing authorization for the adalimumab biosimilar Imraldi from Samsung Bioepis.

Original Article: EMA approval for adalimumab biosimilar Imraldi

NEXT ARTICLE

More From BioPortfolio on "EMA approval for adalimumab biosimilar Imraldi"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...